source
- Sanofi reports shortages of Myozyme and Nexviazyme for Pompe disease after FDA manufacturing warningSanofi has warned that supplies of two medicines used to treat Pompe disease are running low. The company notified patient groups and physicians in the United States and Europe that the shortage af…
- Replimune secures FDA approval for Tudriqev, eyes $1.3 bn peak sales in advanced melanomaReplimune announced FDA approval of its therapy Tudriqev for patients with advanced melanoma who have progressed after PD-1 treatment. Analysts at BMO Capital Markets project the drug could genera…